Impax Laboratories and Perrigo have entered into a collaboration for the development, manufacture and commercialization of an undisclosed extended topical generic drug product. Financial terms were not disclosed. “We are excited to expand our relationship with Perrigo on this product,” said Larry Hsu, Ph.D., president and chief executive officer of Impax Laboratories. In just over two years, Impax has partnered with four different companies on 27 alternative dosage form products, with 18 of the...